TickerFacts.

Johnson & Johnson (JNJ): Cash & Equivalents

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2023-01-01 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$19.71B
As of 2025-12-28
$16.91B
As of 2026-09-27
+15.2%
3-year compound annual growth
$24.54B2007-12-30: $7.77B2008-12-28: $10.77B2010-01-03: $15.81B2011-01-02: $19.36B2012-01-01: $24.54B2012-12-30: $14.91B2013-12-29: $20.93B2014-12-28: $14.52B2016-01-03: $13.73B2017-01-01: $18.97B2017-12-31: $17.82B2018-12-30: $18.11B2019-12-29: $17.30B2021-01-03: $13.98B2022-01-02: $14.49B2023-01-01: $12.89B2023-12-31: $21.86B2024-12-29: $24.11B2025-12-28: $19.71B$19.71B
2007-12-30 Cash & Equivalents (USD) 2025-12-28
Period endedCash & EquivalentsChange YoYSource filing
2025-12-28$19.71B-18.2%2026-02-11, Balance as of period end
2024-12-29$24.11B+10.3%2026-02-11, Balance as of period end
2023-12-31$21.86B+69.6%2025-02-13, Balance as of period end
2023-01-01, Fiscal 2022$12.89Bn/c2024-02-16, Balance as of period end
2022-01-02, Fiscal 2021$14.49B+3.6%2023-02-16, Balance as of period end
2021-01-03, Fiscal 2020$13.98B-19.2%2022-02-17, Balance as of period end
2019-12-29$17.30B-4.4%2021-02-22, Balance as of period end
2018-12-30$18.11B+1.6%2020-02-18, Balance as of period end
2017-12-31$17.82B-6.1%2019-02-20, Balance as of period end
2017-01-01, Fiscal 2016$18.97B+38.2%2019-02-20, Balance as of period end
2016-01-03, Fiscal 2015$13.73B-5.4%2018-02-21, Balance as of period end
2014-12-28$14.52B-30.6%2017-02-27, Balance as of period end
2013-12-29$20.93B+40.3%2016-02-24, Balance as of period end
2012-12-30$14.91B-39.2%2015-02-24, Balance as of period end
2012-01-01, Fiscal 2011$24.54B+26.8%2014-02-21, Balance as of period end
2011-01-02, Fiscal 2010$19.36B+22.4%2013-02-22, Balance as of period end
2010-01-03, Fiscal 2009$15.81B+46.8%2012-02-23, Balance as of period end
2008-12-28$10.77B+38.6%2011-02-25, Balance as of period end
2007-12-30$7.77Bn/a2010-03-01, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Johnson & Johnson (JNJ)2025-12-28$19.71B-18.2%
Eli Lilly & Co (LLY)2025-12-31$7.27B+122.4%
Merck & Co., Inc. (MRK)2025-12-31$14.56B+10.0%
Pfizer Inc (PFE)2025-12-31$1.14B+9.5%
AbbVie Inc. (ABBV)2025-12-31$5.23B-5.3%
Bristol Myers Squibb Co (BMY)2025-12-31$10.21B-1.3%
Abbott Laboratories (ABT)2025-12-31$8.52B+11.9%
Teva Pharmaceutical Industries Ltd (TEVA)2025-12-31$3.56B+7.8%
Regeneron Pharmaceuticals, Inc. (REGN)2025-12-31$3.12B+25.3%

Compare JNJ, LLY, MRK, PFE side by side · Screen every company in Pharmaceutical Preparations ↗